Healthy growth closes out Q420 as the trauma segment recovers in the second half of the year hitting pre-COVID levels.
Despite the rise in COVID cases during Q4, the Trauma Market fared well resulting in positive YoY revenue gains that represented healthy, pre-COVID level volumes. Trauma players cited another quarter of healthy trauma growth, as the second half of the year ended on an upswing (+5.6% vs. H219). Top US market leaders, DePuy Synthes (49.4% Q420 US share), Stryker (27.3%) and Smith & Nephew (9.8%) all reported improved sequential gains.
Among the many topics covered in the comprehensive Q420/FY20 Trauma Market Recap* are:
- Complete Trauma Market Overview
- Companies' Revenues and Market Shares
- Ending the Year on a High Note
- The Future Looks Bright
- Q420 Trauma Regulatory Highlights
The top trauma players reported accelerated sequential growth for the final quarter, most notably in the US. JNJ/DePuy Synthes reported Q4 WW revenues were up +5.2% (+3.6% CC) w/ the US up +10% vs Q3’s WW +1.3% (0.7% CC) and US +4.2% increase. Management reported that Q4 US market recovery and overall global success was due to ...
*The entire article and the links can only be viewed by SmartTRAK subscribers to this module. For more information on how to receive a demo and subscribe, please click here.
SmartTRAK is kicking off 2021 with some exciting new product launches, including Pediatric Trauma. Click the button to see what we have on tap in the coming months.
